HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning To Skin-Care Firm Shows Perils Of Cosmetics-To-Drug Transition

This article was originally published in The Rose Sheet

Executive Summary

FDA's warning letter to skin-care product firm MW Laboratories for marketing unapproved new drugs illustrates the potentially perilous transition from marketing cosmeceuticals to making OTC claims
Advertisement

Related Content

FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics
FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics
Less Tolerant FDA May Flex Enforcement Muscles On Cosmeceuticals - Lawyer
Less Tolerant FDA May Flex Enforcement Muscles On Cosmeceuticals - Lawyer
Advertisement
UsernamePublicRestriction

Register

RS016974

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel